Financial Survey: NexGel (NXGL) vs. Its Peers

NexGel (NASDAQ:NXGL) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its rivals? We will compare NexGel to similar companies based on the strength of its risk, earnings, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares NexGel and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NexGel	$11.42 million	-$3.00 million	-0.32
NexGel Competitors	$1.88 billion	$139.14 million	10.94

NexGel’s rivals have higher revenue and earnings than NexGel. NexGel is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares NexGel and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NexGel	-51.26%	-121.18%	-41.15%
NexGel Competitors	-278.24%	-150.08%	-21.87%

Analyst Recommendations

This is a breakdown of current ratings and target prices for NexGel and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NexGel	1	2	0	0	1.67
NexGel Competitors	4264	10498	18235	825	2.46

NexGel currently has a consensus price target of $40.00, suggesting a potential upside of 792.86%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 22.57%. Given NexGel’s higher possible upside, research analysts plainly believe NexGel is more favorable than its rivals.

Institutional & Insider Ownership

2.2% of NexGel shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 19.8% of NexGel shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

NexGel has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, NexGel’s rivals have a beta of 2.56, suggesting that their average share price is 156% more volatile than the S&P 500.

Summary

NexGel rivals beat NexGel on 9 of the 13 factors compared.

About NexGel

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.